Which company does Cabozantinib come from and how to buy it in the country?

Cabozantinib (Cabozantinib), sold under the brand names Cometriq and Cabometyx, is an anti-cancer drug used to treat thyroid cancer, renal cell carcinoma and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2 and also inhibits AXL and RET. Cabozantinib was discovered and developed by Exelixis.

In November 2012, the U.S. Food and Drug Administration (FDA) approved a capsule formulation of cabozantinib under the name Cometriq for the treatment of patients with medullary thyroid cancer, and the European Union approved a capsule form for the same purpose in 2014. In April 2016, the FDA approved the marketing of cabozantinib tablets as a second-line treatment for kidney cancer, sold under the name Cabometyx. In September of the same year, the European Union also approved the marketing of the drug. The two brands, Cometriq and Cabometyx, have different formulas and are not interchangeable.

The original drug cabozantinib is not on the market in China, so it cannot be included in medical insurance. Patients in need cannot purchase this drug from domestic hospitals and other places, and can only choose it through overseas channels. The original cabozantinib drug marketed overseas includes Japanese, European and Turkish versions. The price of tablets may be more than 30,000 yuan, and the price of capsule preparations may be more than 40,000 yuan (prices may fluctuate due to exchange rates). There are also generic drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. For example, the price of pharmaceuticals produced by Bangladeshi pharmaceutical factories may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), which is relatively cheap.